Additionally, one of the KRASWT/BRAFWT cell lines that was sensitive to MEK inhibition but insensitive to LY3009120 harbors an activating MEK mutation, suggesting that the anti-proliferative mechanism of action of LY3009120 in CRC is mediated in part by the MEK/ERK signaling cascade. This evidence concerns the gene MAP2K7 and colorectal carcinoma.